NOV 17, 202659 MINS READ
Acetyl Hexapeptide-8 (Ac-Glu-Glu-Met-Gln-Arg-Arg-NH2) is a synthetic hexapeptide designed as a biomimetic analog of the SNAP-25 protein's N-terminal domain 1,3. The peptide's molecular architecture enables it to competitively bind to the SNARE (soluble N-ethylmaleimide-sensitive factor attachment protein receptor) complex assembly site, thereby disrupting the stable formation of the SNARE complex without irreversibly damaging any constituent proteins 3,6. This mechanism fundamentally differs from botulinum neurotoxin, which cleaves SNARE proteins; instead, Acetyl Hexapeptide-8 reversibly destabilizes the complex, leading to reduced vesicle fusion efficiency at the neuromuscular junction 5,11.
When the SNARE complex stability is compromised, synaptic vesicles containing acetylcholine cannot effectively dock and fuse with the presynaptic membrane, resulting in decreased neurotransmitter release into the synaptic cleft 1,5. Consequently, muscle fiber contraction intensity diminishes, leading to relaxation of facial muscles responsible for expression lines such as crow's feet, forehead wrinkles, and glabellar lines 2,7. Clinical studies have demonstrated acetylcholine inhibition rates ranging from 31% to over 50% depending on formulation and peptide concentration, with synergistic combinations achieving significantly higher efficacy 12.
The peptide exhibits excellent water solubility (approximately 10 mg/mL in aqueous media), though this can be enhanced through formulation strategies including pH adjustment (optimal range 4.5–6.5), co-solvent systems, and encapsulation technologies 9,3. Importantly, Acetyl Hexapeptide-8 demonstrates thermal sensitivity, with significant activity loss observed above 35°C during processing, necessitating careful temperature control during manufacturing 10,3.
To overcome the inherent challenge of peptide penetration through the stratum corneum, advanced delivery systems have been developed. Liposomal encapsulation of Acetyl Hexapeptide-8 significantly enhances transdermal delivery efficiency by protecting the peptide from enzymatic degradation and facilitating lipid bilayer fusion with skin cell membranes 1. Patent CN202410430 describes a multi-peptide liposome system combining Acetyl Hexapeptide-8 with copper peptides and nonapeptide-1, where the lipid membrane composition (typically phosphatidylcholine, cholesterol, and charged lipids in specific ratios) creates a biocompatible vehicle that increases peptide residence time in dermal layers 1.
Chemical penetration enhancers such as pentylene glycol, EPDM147, and specific alpha-hydroxy acid derivatives (glycolic acid, lactic acid, citric acid at 1.0–5.0% w/w) have been demonstrated to synergistically improve Acetyl Hexapeptide-8 bioavailability 3,9. These agents temporarily modulate stratum corneum lipid organization, creating transient aqueous channels for peptide diffusion. Formulations incorporating 戊二醇 (pentylene glycol) at 1.0% combined with liposomal Acetyl Hexapeptide-8 showed superior wrinkle reduction compared to non-encapsulated controls in 28-day clinical trials 3.
High-concentration Acetyl Hexapeptide-8 formulations (3.0–15.0% w/w) require meticulous pH control to maintain peptide integrity and prevent aggregation or precipitation 9. Buffering systems utilizing phosphate or citrate buffers to maintain pH between 4.5 and 6.5 have proven effective in preserving >50% of initial peptide content after six months of storage at ambient temperature 9. The addition of fruit acid derivatives not only aids solubilization but also provides mild exfoliation benefits that enhance peptide penetration 9.
Polysaccharide polymers including sodium hyaluronate (molecular weight 10–100 kDa), xanthan gum, guar gum, and carboxymethyl cellulose (0.1–2.0% w/w) serve dual functions as viscosity modifiers and peptide stabilizers through hydrogen bonding interactions that shield the peptide from hydrolytic degradation 9. Formulations combining 5.0% Acetyl Hexapeptide-8 with 1.0% low-molecular-weight hyaluronic acid demonstrated synergistic moisturization and wrinkle-filling effects, with the hyaluronic acid providing immediate plumping while the peptide delivered long-term muscle relaxation 6,10.
Dissolving microneedle patches represent an innovative delivery platform that bypasses the stratum corneum barrier entirely 10. Patent CN202331103 describes a microneedle formulation where Acetyl Hexapeptide-8 (8–10% w/w) is co-formulated with sodium hyaluronate in a dissolvable matrix. The microneedles (typical height 500–800 μm, base diameter 200–300 μm) penetrate into the viable epidermis and upper dermis, where they dissolve within 15–30 minutes, releasing the peptide directly into target tissue layers 10. This approach achieves significantly higher local peptide concentrations compared to topical application, with clinical studies showing 40–60% wrinkle depth reduction after 8 weeks of twice-weekly application 10.
The manufacturing process requires careful temperature management: sodium hyaluronate solution is prepared first and cooled to <30°C before adding Acetyl Hexapeptide-8 solution (also maintained at ≤35°C) to prevent thermal deactivation of the peptide 10. The addition of film-forming agents (polyvinyl alcohol, polyvinylpyrrolidone at 1–3% w/w) enhances microneedle mechanical strength, preventing premature breakage during skin insertion 10.
While Acetyl Hexapeptide-8 effectively addresses dynamic wrinkles through neurotransmitter modulation, comprehensive anti-aging requires targeting multiple pathways. Patent CN202509002 describes a rapid-acting anti-wrinkle composition combining Acetyl Hexapeptide-8 (4–12 parts by weight) with dipeptide diaminobutyroyl benzylamide diacetate (2–6 parts), tripeptide-32 (0.1–0.2 parts), Pseudostellaria heterophylla cyclopeptide (0.2–5 parts), and citrus peel extract (4–6 parts) 2. This formulation addresses both immediate wrinkle relaxation and long-term collagen synthesis stimulation.
Dipeptide diaminobutyroyl benzylamide diacetate acts as a sodium channel blocker, providing an alternative mechanism to reduce muscle contraction that complements Acetyl Hexapeptide-8's SNARE inhibition 2,5. The combination achieves acetylcholine inhibition rates exceeding 45%, significantly higher than either peptide alone 2. Tripeptide-32 stimulates fibroblast proliferation and extracellular matrix production, while Pseudostellaria heterophylla cyclopeptide provides antioxidant protection against reactive oxygen species that degrade collagen 2.
Patent CN202102226 presents another synergistic formulation combining Acetyl Hexapeptide-8 (0.5–1.0% w/w), snake venom-like tripeptide (0.05–1.0% w/w), and hexapeptide-11 (0.05–1.0% w/w) 5. Snake venom-like tripeptide functions as an acetylcholine receptor antagonist, competitively blocking postsynaptic binding sites and preventing sodium channel opening—a mechanism orthogonal to Acetyl Hexapeptide-8's presynaptic action 5. Hexapeptide-11 upregulates genes encoding collagen I, collagen III, and elastin in dermal fibroblasts, improving skin elasticity and reducing static wrinkles 5. Clinical trials with this triple-peptide system showed 35% reduction in crow's feet depth and 28% improvement in skin firmness after 56 days of twice-daily application 5.
The integration of botanical extracts with Acetyl Hexapeptide-8 provides multifaceted benefits including antioxidant protection, anti-inflammatory effects, and skin barrier reinforcement. Patent CN202504300 describes a formulation combining peptide liposomes (containing Acetyl Hexapeptide-8, copper peptides, and nonapeptide-1) with Gomphrena globosa extract, Stevia rebaudiana leaf/stem extract, and Theobroma grandiflorum seed butter 1.
Gomphrena globosa extract contains flavonoids and polysaccharides that provide immediate film-forming and wrinkle-filling effects, complementing Acetyl Hexapeptide-8's muscle-relaxing action for rapid visible results 1. Stevia rebaudiana extract, rich in steviol glycosides and phenolic compounds, synergizes with copper peptides to enhance collagen synthesis through upregulation of TGF-β signaling pathways 1. In vitro studies demonstrated 62% increase in procollagen I C-peptide secretion when Stevia extract was combined with copper peptides compared to copper peptides alone 1. Theobroma grandiflorum seed butter provides essential fatty acids (oleic acid 40–45%, stearic acid 30–35%, palmitic acid 8–10%) that strengthen the lipid barrier, reduce transepidermal water loss (TEWL), and improve skin suppleness 1.
Yeast extract combined with Acetyl Hexapeptide-8 (mass ratio 1:3 to 1:8) has been shown to increase elastase inhibition rates, with optimal formulations achieving 55–60% inhibition compared to 30–35% for Acetyl Hexapeptide-8 alone 4. The yeast extract contributes β-glucans, amino acids, and B-vitamins that enhance skin barrier function and provide additional moisturization 4.
Clinical evaluation of Acetyl Hexapeptide-8 efficacy employs multiple objective measurement techniques including profilometry (wrinkle depth and volume quantification), cutometry (skin elasticity parameters R2, R5, R7), and corneometry (stratum corneum hydration). A formulation containing 5% Acetyl Hexapeptide-8 in a liposomal delivery system demonstrated the following results in a 12-week, double-blind, placebo-controlled study with 60 female subjects (aged 35–55 years) 1:
The multi-peptide formulation described in patent CN202102226 (Acetyl Hexapeptide-8 + snake venom-like tripeptide + hexapeptide-11) achieved 35% reduction in periorbital wrinkle depth and 28% improvement in skin firmness (measured by cutometry) after 8 weeks of twice-daily application in a cohort of 45 subjects 5. Notably, improvements were observed as early as 2 weeks, with progressive enhancement through the study duration, indicating both immediate muscle-relaxing effects and cumulative collagen remodeling benefits 5.
In vitro acetylcholine inhibition assays using PC12 neuronal cell lines provide mechanistic validation of Acetyl Hexapeptide-8 activity. The peptide at 10 μM concentration typically achieves 30–40% inhibition of acetylcholine release induced by potassium chloride depolarization 12. Synergistic combinations demonstrate significantly enhanced inhibition:
These data confirm that multi-peptide formulations achieve synergistic rather than merely additive effects, likely due to complementary mechanisms targeting different steps in neuromuscular signal transduction 5,12.
Acetyl Hexapeptide-8 exhibits excellent safety characteristics with acute oral toxicity (LD50) exceeding 2000 mg/kg in rodent models, classified as "practically non-toxic" under GHS criteria 3,13. Dermatological safety assessments including repeat insult patch testing (RIPT), cumulative irritation testing, and ocular irritation testing (modified Draize) consistently demonstrate non-irritating and non-sensitizing properties at concentrations up to 10% w/w 7,13.
Cytotoxicity assays using human dermal fibroblasts (HDF) and keratinocytes (HaCaT) show cell viability >95% at concentrations up to 1000 μg/mL, with IC50 values exceeding 5000 μg/mL 13. Importantly, Acetyl Hexapeptide-8 does not induce the permanent paralysis or muscle atrophy associated with botulinum toxin, as its mechanism involves reversible competitive inhibition rather than proteolytic cleavage of SNARE proteins 3,6. This allows for daily use without cumulative toxicity concerns, and effects are fully reversible upon discontinuation 11.
High-concentration Acetyl Hexapeptide-8 serums (5–15% w/w) represent the most efficacious delivery format for targeted wrinkle treatment 9. These formulations typically employ lightweight, fast-absorbing bases comprising:
| Org | Application Scenarios | Product/Project | Technical Outcomes |
|---|---|---|---|
| SHENZHEN JYMED TECHNOLOGY CO. LTD. | Premium anti-aging skincare products requiring comprehensive wrinkle treatment targeting both dynamic expression lines and static wrinkles, suitable for facial care applications in cosmetic formulations. | Multi-Peptide Liposome Anti-Wrinkle Serum | Liposomal delivery system combining Acetyl Hexapeptide-8 with copper peptides and nonapeptide-1 enhances transdermal penetration and provides both immediate wrinkle reduction through acetylcholine inhibition and long-term collagen synthesis stimulation, complemented by Gomphrena globosa extract for instant wrinkle-filling effects. |
| SHENZHEN JX BIO PHARMACEUTICAL CO. LTD. | Fast-acting anti-wrinkle cosmetic products for consumers seeking rapid visible results, applicable in serums and creams targeting crow's feet, forehead lines, and glabellar wrinkles. | Rapid Anti-Wrinkle Peptide Complex | Synergistic formulation combining Acetyl Hexapeptide-8 (4-12 parts), dipeptide diaminobutyroyl benzylamide diacetate (2-6 parts), tripeptide-32 (0.1-0.2 parts), and Pseudostellaria heterophylla cyclopeptide achieves acetylcholine inhibition rates exceeding 45%, significantly higher than single peptide applications, with enhanced antioxidant protection and collagen synthesis stimulation. |
| HANGZHOU FANLIN TECHNOLOGY CO. LTD. | Concentrated anti-wrinkle treatment serums and essences for professional skincare applications requiring maximum peptide efficacy and stability in resource-optimized formulations. | Penetration-Enhanced Acetyl Hexapeptide-8 Essence | High-concentration Acetyl Hexapeptide-8 formulation (3.0-15.0% w/w) utilizing chemical penetration enhancers (pentylene glycol, EPDM147) and liposomal encapsulation technology, with pH buffering systems (4.5-6.5) maintaining >50% peptide stability after six months storage, combined with fruit acid derivatives for enhanced dermal delivery. |
| SHANDONG KESIDAMEI BIOTECHNOLOGY CO. LTD. | Comprehensive anti-aging skincare products targeting both dynamic wrinkles through neurotransmitter modulation and static wrinkles through extracellular matrix enhancement, suitable for mature skin care regimens. | Triple-Peptide Anti-Wrinkle Essence | Multi-mechanism formulation combining Acetyl Hexapeptide-8 (0.5-1.0%), snake venom-like tripeptide (0.05-1.0%), and hexapeptide-11 (0.05-1.0%) achieves 35% reduction in crow's feet depth and 28% improvement in skin firmness after 56 days through complementary presynaptic SNARE inhibition, postsynaptic acetylcholine receptor blockade, and collagen synthesis upregulation. |
| JIANGSU JICUI FUNCTIONAL MATERIALS RESEARCH INSTITUTE CO. LTD. | Advanced transdermal delivery systems for targeted wrinkle treatment requiring direct dermal peptide delivery without topical application limitations, suitable for periorbital and forehead wrinkle treatment patches. | Dissolving Microneedle Patch with Acetyl Hexapeptide-8 | Innovative dissolving microneedle delivery system (500-800 μm height) containing 8-10% Acetyl Hexapeptide-8 co-formulated with sodium hyaluronate bypasses stratum corneum barrier, dissolving within 15-30 minutes to deliver peptide directly into viable epidermis and upper dermis, achieving 40-60% wrinkle depth reduction after 8 weeks of twice-weekly application. |